Introduction
Growth failure is the most frequent endocrine abnormality observed in patients with SCD. Decreased synthesis of IGF-I might be secondary to a disturbed GH-IGF-I axis and defective GH secretion has been reported in some patients. Infarction, atrophy, and hemorrhage may occur in the pituitary gland in SCD during or following the vaso-occlusive crisis.
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Results
Objectives
To define the possible abnormalities of pituitary gland in sickle-cell disease (SCD) we measured the circulating concentrations of insulin-like Growth factor -I (IGF-I) and studied the Magnetic Resonance Imaging (MRI) of the pituitary gland in 7 adolescents and young adults with SCD with short stature (HtSDS < -2) and history of recurrent painful crisis.
Seven patients with SCD (age : 24.2 +/-4.5 years) and short stature (HtSDS = 2.5 +/-0.4) and history of severe and recurrent vaso-occlusive crisis ( at least 3 in the past 3 years) were studied. All were transfusion -dependent, with full pubertal development (Tanner's stage 5) (euogonadal). They were regularly transfused since early childhood and underwent chelation therapy using desferrioxamine which was replaced by deferasirox for the last 4 -5 years.
In the 7 patients with SCD circulating IGF-I were decreased (IGF-I SDS = -2.1+/-0.5) compared to adults standards. Pituitary MR imaging showed abnormalities in 4/7 of these patients in the form of heterogeneous appearance of the anterior pituitary, presence of single or multiple hypointense foci due to hemosiderin deposition in the pituitary (4/7) and significantly decreased (2/7) or increased volume (1/7). These lesions can be explained by hemosiderosis of the gland and/or ischemia during the vaso-occlusive crisis MRI in this study and CT imaging of the pituitary gland in patients with SCD (1) showed significant abnormalities of the gland in the form of deposits of hemosiderin as well as volume changes.
